Alkem Laboratories (NSE:ALKEM) Piotroski F-Score: 3 (As of Jun. 27, 2026) — 50% Below Median


NSE:ALKEM Alkem Laboratories Ltd NSE:ALKEM
96 GF Score
Price ₹5,425.00
GF Value ₹6,066.47
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Alkem Laboratories Piotroski F-Score?

Alkem Laboratories NSE:ALKEM -0.06% 96 Piotroski F-Score is 3 as of Jun. 27, 2026, which is 50% below its 10-year median of 6.00. GuruFocus rates NSE:ALKEM with a GF Score™ of 96/100 and a GF Value™ of ₹6,066.47 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 981 Drug Manufacturers companies, Alkem Laboratories ranks worse than 78.29% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alkem Laboratories has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Alkem Laboratories's Piotroski F-Score or its related term are showing as below:

NSE:ALKEM' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 3

During the past 13 years, the highest Piotroski F-Score of Alkem Laboratories was 8. The lowest was 3. And the median was 6.

Alkem Laboratories  (NSE:ALKEM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Alkem Laboratories Piotroski F-Score Related Terms


Alkem Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Alkem Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkem Laboratories Piotroski F-Score Chart

Alkem Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 8.00 5.00 3.00

Alkem Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 0.00 0.00 0.00 3.00

NSE:ALKEM vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkem Laboratories Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Alkem Laboratories's Piotroski F-Score falls into.


NSE:ALKEM
96GF Score
Alkem Laboratories Ltd NSE:ALKEM
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹23,018 Mil.
Cash Flow from Operations was ₹19,630 Mil.
Revenue was ₹147,123 Mil.
Gross Profit was ₹96,195 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (176911 + 208729.7) / 2 = ₹192820.35 Mil.
Total Assets at the begining of this year (Mar25) was ₹176,911 Mil.
Long-Term Debt & Capital Lease Obligation was ₹8,692 Mil.
Total Current Assets was ₹122,105 Mil.
Total Current Liabilities was ₹47,827 Mil.
Net Income was ₹21,655 Mil.

Revenue was ₹129,645 Mil.
Gross Profit was ₹82,003 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (155749 + 176911) / 2 = ₹166330 Mil.
Total Assets at the begining of last year (Mar24) was ₹155,749 Mil.
Long-Term Debt & Capital Lease Obligation was ₹5,783 Mil.
Total Current Assets was ₹109,458 Mil.
Total Current Liabilities was ₹39,650 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alkem Laboratories's current Net Income (TTM) was 23,018. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alkem Laboratories's current Cash Flow from Operations (TTM) was 19,630. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=23018/176911
=0.13011062

ROA (Last Year)=Net Income/Total Assets (Mar24)
=21654.8/155749
=0.13903653

Alkem Laboratories's return on assets of this year was 0.13011062. Alkem Laboratories's return on assets of last year was 0.13903653. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Alkem Laboratories's current Net Income (TTM) was 23,018. Alkem Laboratories's current Cash Flow from Operations (TTM) was 19,630. ==> 19,630 <= 23,018 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=8692.3/192820.35
=0.04507979

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=5783.3/166330
=0.03477004

Alkem Laboratories's gearing of this year was 0.04507979. Alkem Laboratories's gearing of last year was 0.03477004. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=122105.2/47827
=2.55305999

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=109458.2/39649.8
=2.76062427

Alkem Laboratories's current ratio of this year was 2.55305999. Alkem Laboratories's current ratio of last year was 2.76062427. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Alkem Laboratories's number of shares in issue this year was 119.568. Alkem Laboratories's number of shares in issue last year was 119.567. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=96195/147122.7
=0.653842

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=82002.6/129645.2
=0.63251551

Alkem Laboratories's gross margin of this year was 0.653842. Alkem Laboratories's gross margin of last year was 0.63251551. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=147122.7/176911
=0.83161985

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=129645.2/155749
=0.83239828

Alkem Laboratories's asset turnover of this year was 0.83161985. Alkem Laboratories's asset turnover of last year was 0.83239828. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+0+0+1+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alkem Laboratories has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Alkem Laboratories (NSE:ALKEM) has a Piotroski F-Score of 3 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Alkem Laboratories and its competitors. This is 50% below median its historical median of 6.00. Over the past decade, Alkem Laboratories' Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Alkem Laboratories ranks #768 out of 981 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is Alkem Laboratories' Piotroski F-Score too high?
Alkem Laboratories' current Piotroski F-Score of 3 is 50% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Alkem Laboratories' value of 3 is 40% below this industry median. Based on the distribution chart, Alkem Laboratories ranks #768 out of 981 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alkem Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkem Laboratories' Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alkem Laboratories ranks #768 out of 981 companies for Piotroski F-Score. This places Alkem Laboratories in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Alkem Laboratories' value of 3 is 40% below this benchmark. Historically, Alkem Laboratories' own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Alkem Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkem Laboratories's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Alkem Laboratories and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkem Laboratories's current Piotroski F-Score is 3, which is 50% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alkem Laboratories (NSE:ALKEM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹6,066.47, compared to a current price of ₹5,425.00 — trading 10.6% below its estimated fair value. The current Piotroski F-Score is 3, which is 50% below median its 10-year median of 6.00 and 40% below the Drug Manufacturers industry median of 5.00. Alkem Laboratories' overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Alkem Laboratories (NSE:ALKEM), the current Piotroski F-Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?

Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued. The current stock price of ₹5,425.00 is trading 10.6% below its estimated GF Value™ of ₹6,066.47. GuruFocus considers Alkem Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:ALKEM:

  • Piotroski F-Score: 3 (50% below median its 10-year median of 6.00)
  • GF Value™: ₹6,066.47 vs. price of ₹5,425.00 (10.6% below fair value)
  • GF Score™: 96/100 with 1 warning sign
  • Industry Position: 40% below the Drug Manufacturers median (#768 of 981)

No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alkem Laboratories Business Description

Other Exchanges 539523:India
Address Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
96GF Score

Get the complete analysis for NSE:ALKEM

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5,425.00
Price
₹6,066.47
GF Value